Literatura científica selecionada sobre o tema "Stambomycin"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Stambomycin".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Stambomycin"
Wang, Yongchen, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Gregory L. Challis e Edward A. Anderson. "Synthesis of the C50 diastereomers of the C33–C51 fragment of stambomycin D". Organic Chemistry Frontiers 9, n.º 2 (2022): 445–49. http://dx.doi.org/10.1039/d1qo01635k.
Texto completo da fonteSong, Lijiang, Luisa Laureti, Christophe Corre, Pierre Leblond, Bertrand Aigle e Gregory L. Challis. "Cytochrome P450-mediated hydroxylation is required for polyketide macrolactonization in stambomycin biosynthesis". Journal of Antibiotics 67, n.º 1 (13 de novembro de 2013): 71–76. http://dx.doi.org/10.1038/ja.2013.119.
Texto completo da fonteSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle e Kira J. Weissman. "Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins". Nature Communications 13, n.º 1 (26 de janeiro de 2022). http://dx.doi.org/10.1038/s41467-022-27955-z.
Texto completo da fonteSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle e Kira J. Weissman. "Author Correction: Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins". Nature Communications 13, n.º 1 (6 de outubro de 2022). http://dx.doi.org/10.1038/s41467-022-33524-1.
Texto completo da fonteLim, Jieyan, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Minh Tran, Alice Bernasconi, Araceli Blanco, Lijiang Song, Gregory L. Challis e Edward A. Anderson. "Synthesis of the C1–C27 Fragment of Stambomycin D Validates Modular Polyketide Synthase-Based Stereochemical Assignments". Organic Letters, 8 de setembro de 2021. http://dx.doi.org/10.1021/acs.orglett.1c02650.
Texto completo da fonteTeses / dissertações sobre o assunto "Stambomycin"
Su, Li. "Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches". Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Texto completo da fonteThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation